Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Mandatory Filings Under CFIUS New Rules

Client Alert
December 11, 2020

On September 15, 2020, the Committee on Foreign Investment in the United States (“CFIUS”) promulgated a final rule modifying its mandatory declaration requirements for certain foreign investment transactions involving “TID US businesses” (sensitive U.S. businesses dealing in critical technologies, critical infrastructure and sensitive personal data) dealing in “critical technologies” – i.e., U.S. businesses that produce, design, test, manufacture, fabricate, or develop one or more critical technologies. The new rule also makes amendments to the definition of the term “substantial interest” (used to determine whether a foreign government has a substantial interest in an entity). The final rule became effective on October 15, 2020.

For background purposes, CFIUS is an interagency committee authorized to review certain transactions involving foreign investment in the United States and certain real estate transactions by foreign persons, in order to determine the effect of such transactions on the national security of the United States. 

The new rule renders it critical for parties to a potentially covered transaction to conduct due diligence with legal counsel regarding the classification of the technology of a U.S. company under export control laws.

Prior to the new rule, filings were mandatory for covered transactions involving 27 sensitive industries (31 C.F.R. Part 801 – Annex A). [i] By eliminating the requirement that the critical technology falls within one of 27 industries identified by CFIUS, a filing will now be required for a covered transaction involving a TID US business that deals in critical technologies for which a “U.S. regulatory authorization” would be required to export, re-export, transfer (in-country) or retransfer the technologies to a certain foreign person.

Under the former rule, a foreign government would have a substantial interest in an entity with a general partner (or managing member or equivalent) if the foreign government held a 49% or greater interest (either voting or economic) in the general partner. Under the new rule, this requirement pertains to instances where the activities of the entity are primarily directed, controlled, or coordinated by or on behalf of the general partner. Note that a general partner is deemed to direct, control, or coordinate such activities by contracting a third party to perform such services.

The new rule clarifies how indirect interests in a general partner (or managing member or equivalent) will be calculated. Under the current rule, for purposes of calculating substantial interest, a parent is deemed to hold 100% of only the voting interest of its subsidiary. Under the new rule, a parent will be deemed to hold 100% of the voting and economic interest of its subsidiary.

CFIUS filing is mandatory when a foreign person (a) makes a direct investment, or acquires a direct interest, in a U.S. business that is a covered transaction in a U.S. critical technology business or (b) individually holds, or is part of a group of foreign persons that in the aggregate holds, a direct or indirect 25% or more voting interest in the foreign investor identified in clause (a). If the foreign investor is a partnership that is controlled by a general partner, then the 25% share referenced in clause (b) is based on the foreign person’s share in the general partner. A parent is deemed to own 100% of the interest held by its subsidiary. 

Based on the foregoing, it will be important for a U.S. company contemplating a potentially covered transaction to review with legal counsel the effects of the new CFIUS rule.

If you have questions regarding CFIUS filing, please contact Robert Q. Lee at rqlee@bmdpl.com.

[i] (31 C.F.R. Part 801 – Annex A) 

List of Pilot Program Industries 1. Aircraft Manufacturing (NAICS Code: 336411) 2. Aircraft Engine and Engine Parts Manufacturing (NAICS Code: 336412) 3. Alumina Refining and Primary Aluminum Production (NAICS Code: 331313) 4. Ball and Roller Bearing Manufacturing (NAICS Code: 332991) 5. Computer Storage Device Manufacturing (NAICS Code: 334112) 6. Electronic Computer Manufacturing (NAICS Code: 334111) 7. Guided Missile and Space Vehicle Manufacturing (NAICS Code: 336414) 8. Guided Missile and Space Vehicle Propulsion Unit and Propulsion Unit Parts Manufacturing (NAICS Code: 336415) 9. Military Armored Vehicle, Tank, and Tank Component Manufacturing (NAICS Code: 336992) 10. Nuclear Electric Power Generation (NAICS Code: 221113) 11. Optical Instrument and Lens Manufacturing (NAICS Code: 333314) 12. Other Basic Inorganic Chemical Manufacturing (NAICS Code: 325180) 13. Other Guided Missile and Space Vehicle Parts and Auxiliary Equipment Manufacturing (NAICS Code: 336419) 14. Petrochemical Manufacturing (NAICS Code: 325110) 15. Powder Metallurgy Part Manufacturing (NAICS Code: 332117) 16. Power, Distribution, and Specialty Transformer Manufacturing (NAICS Code: 335311) 17. Primary Battery Manufacturing (NAICS Code: 335912) 18. Radio and Television Broadcasting and Wireless Communications Equipment Manufacturing (NAICS Code: 334220) 19. Research and Development in Nanotechnology (NAICS Code: 541713) 20. Research and Development in Biotechnology (except Nanobiotechnology) (NAICS Code: 541714) 21. Secondary Smelting and Alloying of Aluminum (NAICS Code: 331314) 22. Search, Detection, Navigation, Guidance, Aeronautical, and Nautical System and Instrument Manufacturing (NAICS Code: 334511) 23. Semiconductor and Related Device Manufacturing (NAICS Code: 334413) 24. Semiconductor Machinery Manufacturing (NAICS Code: 333242) 25. Storage Battery Manufacturing (NAICS Code: 335911) 26. Telephone Apparatus Manufacturing (NAICS Code: 334210) 27. Turbine and Turbine Generator Set Units Manufacturing (NAICS Code: 333611)

Robert Q. LeeCFIUScritical technologiesforeign investment transactionsInternational Law
Client Alert

The Future of the Families First Coronavirus Response Act

February 3, 2021Over the last year we all have had to adjust to the new normal ushered in by the coronavirus pandemic. Schools and daycares closed, businesses transitioned from in-office work to work from home, bars and restaurants have closed their doors...all to slow the spread and try to prevent this pandemic from spiraling out of control. The start of the pandemic was utter pandemonium. Working parents trying to balance both caring for their now at-home children and their livelihood. Businesses trying to decide how to implement leave policies with limited information. Employees determining if they could financially afford to take time off. We were all flying by the seat of our pants trying to adjust to our new normal.Client Alert

Ohio Supreme Court Clarifies Medical Statute of Limitations

February 1, 2021The Ohio Supreme Court issued a decision in late December that clarifies and finalizes the Ohio law regarding the period of time in which patients can assert claims for medical malpractice. The Court was examining the interplay between three different statutes being the statute of limitations, the statute of repose, and the savings statute.Client Alert

Ohio Hospitals and Healthcare Clinics: It’s Time to Revisit Your Billing and Collection Practices

February 1, 2021According to a recent Cuyahoga County case, certain healthcare entities may not be protected from liability when engaging in unfair or deceptive billing acts. This decision is consistent with the growing trend across the country to encourage price transparency and eliminate unfair surprise billing practices by health care organizations. Now is the time for hospitals and other health care organizations to revisit their billing and collection policies and procedures to confirm that they are legally defensible and consistent with best practices.Client Alert

HIPAA Business Associate Agreements: Why These Contracts Matter

January 27, 2021No one loves drafting, reading or negotiating HIPAA Business Associate Agreements (BAAs). Yet many of us need to do so, and some of us do so daily. They are often boring, dense and technical, but BAAs are important from both a legal and a business perspective, and they deserve our attention. Failure to enter a BAA when one is required can constitute a HIPAA violation that results in substantial liability, as demonstrated by certain recent Department of Health & Human Services (HHS) settlements.1 A business associate who makes a disclosure that is not authorized by the applicable BAA or required by law can be subject to civil and, in some cases, criminal penalties. Further, parties are often presented with BAAs that contain onerous one-sided indemnification and other provisions that can be devasting to an organization in the event of a HIPAA breach. The significance of a BAA is often not fully understood by the parties until something goes wrong (e.g., a HIPAA security incident or breach, an Office of Civil Rights (OCR) audit or a fracture in the relationship between the parties) and, at that point, there is limited opportunity to mitigate legal and business risk. Ideally, attention should be given at the commencement of the business associate relationship, when the parties are able, to thoughtfully addressing regulatory requirements, planning and preparing for potential adverse events and appropriately allocating risk among the parties. As with most healthcare regulatory compliance initiatives, a proactive approach with respect to BAAs is preferable. This article provides a broad overview of certain BAA requirements and some practical negotiating tips for the parties involved.Client Alert

“I’m Out Of Here!” Now What?

January 27, 2021We all know that the healthcare industry is experiencing a wave of integration. This trend has been evident for many years. Fewer physicians are willing to assume the legal, financial and other business risks associated with owning their own practices. More and more physicians, including anesthesiologists, are becoming employed by large physician groups, health systems and national providers. This shift necessarily involves not only entry into new employment arrangements but also the termination of existing relationships. And those terminations are often governed by written employment agreements, state and federal healthcare laws and employer benefit plans and other policies and procedures. Before pursuing their next opportunity, physicians should pause for a moment and first attend to the arrangement that they are leaving. Departing physicians need to understand their legal rights and obligations when leaving their current employment relationships in order to avoid unintended consequences and detrimental missteps along the way. Here are a few words of practical advice for physicians contemplating an exit from their current employment arrangements.
Older posts
Newer posts